Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $246.73, moving +0.48% from the previous trading session.

Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Amgen (AMGN) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $243.51, marking a -0.55% move from the previous day.

Amgen (AMGN) Stock Moves -0.21%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $244.85, moving -0.21% from the previous trading session.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

by Zacks Equity Research

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

by Zacks Equity Research

With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.

The Zacks Analyst Blog Highlights Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker

by Zacks Equity Research

Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.

Amgen (AMGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $235.70, marking a -0.45% move from the previous day.

Sheraz Mian headshot

Top Research Reports for Microsoft, Amgen & Honeywell

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amgen Inc. (AMGN), and Honeywell International Inc. (HON).

Amgen (AMGN) Stock Moves -0.38%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $245.48, moving -0.38% from the previous trading session.

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

by Zacks Equity Research

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius (RDUS) to Stop Work on Abaloparatide Transdermal System

by Zacks Equity Research

Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.

Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II

by Zacks Equity Research

Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.

Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study

by Zacks Equity Research

Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.

Amgen (AMGN) Up 6.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

by Zacks Equity Research

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.